

Silva Pharmaceuticals Limited

Un-Audited Financial Statements (Third Quarter)

For the Period from 01 July, 2025 to 31 March, 2026


SILVA PHARMACEUTICALS LTD.
Statement of Financial Position (Un-Audited)
As at 31 March, 2026

Particulars	Notes	Amount in Taka	
		31-Mar-26	30-Jun-25
ASSETS			
Non Current Assets		1,383,857,283	1,422,482,307
Property, Plant & Equipment	3.00	1,053,307,628	1,092,403,671
Intangible Assets	4.00	2,239,920	2,421,535
Right-of-use asset (ROU)	5.00	3,449,857	4,377,163
Capital work-in-Progress	6.00	324,859,878	323,279,938
Current Assets		748,029,691	829,838,514
Inventories	7.00	406,946,308	443,011,615
Trade and Other Receivables	8.00	194,346,903	229,617,998
Advances, Deposits and Prepayments	9.00	62,940,850	54,404,706
Fixed Deposits Receipts (FDR)	10.00	-	64,030,846
Cash and Cash Equivalents	11.00	83,795,630	38,773,349
Total Assets		2,131,886,974	2,252,320,821
SHAREHOLDERS EQUITY AND LIABILITIES:			
Equity attributable to the Shareholders		2,014,127,626	2,113,040,947
Share Capital	12.00	1,365,000,000	1,365,000,000
Retained Earnings	13.00	649,127,626	748,040,947
Non-Current Liabilities		82,454,706	83,580,827
Deferred Tax Liabilities	14.00	81,018,583	81,270,136
Lease liabilities	15.00	1,436,123	2,310,691
Current Liabilities		35,304,642	55,699,047
Lease liabilities	15.00	1,013,734	1,066,472
Trade and Other Payables	16.00	14,305,023	9,971,279
Unclaimed Dividend Account	17.00	96,694	139,158
Short Term Finance	18.00	-	28,219,737
Provision for Expenses	19.00	19,889,191	16,302,401
Total Liabilities		117,759,348	139,279,874
Total Equity & Liabilities:		2,131,886,974	2,252,320,821
Net Assets Value (NAV) per share	29.00	14.76	15.48
Number of Shares used to compute NAV		136,500,000	136,500,000

The annexed notes from an integral part of these financial statements.



Chairman



Managing Director / CEO (CC)



Director



Chief Financial Officer



Company Secretary

Place: Dhaka;

Dated: April 30, 2026

Silva Pharmaceuticals Ltd


Statements of Profit or Loss and Other Comprehensive Income (Un-Audited) For the Third Quarter ended 31 March, 2026

Particulars	Notes	Amount in Taka			
		Third Quarter ended Results		Quarterly Results	
		01/07/2025 to 31/03/2026	01/07/2024 to 31/03/2025	01/01/2026 to 31/03/2026	01/01/2025 to 31/03/2025
Revenue from Net Sales	20.00	255,260,286	309,278,213	80,286,379	107,643,330
Cost of goods sold	21.00	(169,189,258)	(208,053,777)	(46,045,176)	(66,507,840)
Gross Profit		86,071,028	101,224,436	34,241,203	41,135,490
Operating expenses		(182,084,346)	(176,401,278)	(61,293,638)	(58,236,113)
Administrative Expenses	22.00	(31,362,422)	(31,355,003)	(12,469,710)	(10,182,642)
Selling & Distribution Expenses	23.00	(150,721,924)	(145,046,275)	(48,823,928)	(48,053,471)
Operating Income		(96,013,318)	(75,176,842)	(27,052,435)	(17,100,623)
Financial expenses	24.00	(2,756,012)	(3,505,820)	(128,756)	(1,569,483)
Interest and Other income	25.00	2,872,839	4,971,744	644,582	1,606,251
Profit before WPPF and Welfare Fund		(95,896,491)	(73,710,918)	(26,536,609)	(17,063,855)
Workers' Profit Participation and Welfare Fund (WPP&WF)	26.00	-	-	-	-
Profit before Income Tax		(95,896,491)	(73,710,918)	(26,536,609)	(17,063,855)
Income Tax Expenses:		(3,016,830)	(3,965,940)	(884,490)	(1,576,670)
Current Tax Expenses	27.01	(3,268,383)	(3,567,345)	(968,269)	(1,452,013)
Deferred Tax (expenses)/ Income	27.02	251,553	(398,595)	83,779	(124,657)
Net Profit after tax		(98,913,321)	(77,676,858)	(27,421,099)	(18,640,525)
Other Comprehensive Income		-	-	-	-
Total comprehensive income for the period		(98,913,321)	(77,676,858)	(27,421,099)	(18,640,525)
Earnings Per Share (EPS)	28.00	(0.72)	(0.57)	(0.20)	(0.14)
Number of Shares used to compute EPS		136,500,000	136,500,000	136,500,000	136,500,000

The annexed notes from an integral part of these financial statements.



Chairman


30.04.2026


Managing Director / CEO (CC)



Director



Chief Financial Officer



Company Secretary

Place: Dhaka;

Dated: April 30, 2026


SILVA PHARMACEUTICALS LTD.
Statement of Changes in Equity (Un-Audited)
For the Third Quarter ended 31 March, 2026

Particulars	<i>(Amount in Taka)</i>		
	Share Capital	Retained Earnings	Total
Balance as on 1st July, 2025	1,365,000,000	748,040,947	2,113,040,947
Net profit after tax during the period	-	- (98,913,321)	(98,913,321)
Dividend for the year 2024-2025	-	-	-
Balance as at 31 March, 2026	1,365,000,000	649,127,626	2,014,127,626

For the Third Quarter ended 31 March, 2025

Particulars	<i>(Amount in Taka)</i>		
	Share Capital	Retained Earnings	Total
Balance as on 1st July, 2024	1,365,000,000	890,949,495	2,255,949,495
Net profit after tax during the period	-	(77,676,858)	(77,676,858)
Dividend Paid in Cash	-	(6,746,505)	(6,746,505)
Balance as at 31 March, 2025	1,365,000,000	806,526,132	2,171,526,132

The annexed notes from an integral part of these financial statements.



 Chairman


 30.04.2026


 Managing Director / CEO (CC)



 Director



 Chief Financial Officer



 Company Secretary


Place: Dhaka;
 Dated: April 30, 2026

SILVA PHARMACEUTICALS LTD.
Statement of Cash Flows (Un-Audited)
For the Third Quarter ended 31 March, 2026

Particulars	Notes	Amount in Taka	
		01/07/2025 to 31/03/2026	01/07/2024 to 31/03/2025
Cash flows from Operating Activities			
Cash received from Customers	30.00	290,387,944	319,008,559
Cash received from non-operating income	31.00	3,016,276	4,409,976
Cash Paid to Suppliers	32.00	(81,501,710)	(93,462,504)
Cash Paid to Employees	33.00	(150,861,054)	(161,482,817)
Cash Paid for Others	34.00	(43,505,999)	(26,920,740)
Cash payment for Financial Expenses		(2,488,028)	(3,153,828)
Income Tax Paid		(2,906,988)	(2,336,308)
Net cash flows from operating activities (A)*	39.00	12,140,441	36,062,338
Cash flows from Investing Activities			
Acquisition of Property, Plant and Equipment		(111,575)	-
Cash Payments for Capital Work-in-progress		(1,579,940)	(5,192,677)
Cash received/Payments from/to FDR		64,030,846	4,894,890
Net cash inflows/(outflows) used in investing activities (B)		62,339,331	(297,787)
Cash flows from Financing Activities			
Short Term Loan received/(Repaid)		(28,219,737)	(9,914,645)
Cash payment towards lease liabilities		(1,195,290)	(1,297,291)
Cash Dividend Paid		(42,464)	(6,713,709)
Net cash inflows/(outflows) provided financing activities (C)		(29,457,491)	(17,925,645)
Net increase/(decrease) of Cash and Cash Equivalents (A+B+C)		45,022,281	17,838,906
Cash and Cash Equivalents at the beginning of the period		38,773,349	38,692,915
Cash and Cash Equivalents at the end of the period		83,795,630	56,531,821
Net Operating Cash Flow Per Share (NOCFPS)	37.00	0.09	0.26
Number of Shares used to compute NOCFPS		136,500,000	136,500,000

*Refer to Note 39.00 for a reconciliation between net profit with cash flows from operating activities.

The annexed notes from an integral part of these financial statements.


Chairman


30.04.2026
Managing Director / CEO (CC)


Director


Chief Financial Officer


Company Secretary

Place: Dhaka;
Dated: April 30, 2026

Silva Pharmaceuticals Limited
Selected Notes to the Financial Statements (Un-Audited)
For the Third Quarter ended 31 March, 2026

1.00 About the Company

1.01 Formation and Legal Status:

Silva Pharmaceuticals Limited (the 'Company') was incorporated in Bangladesh on 24 April 2001 as a Private Limited Company and subsequently converted into Public Limited Company on 22 April, 2014 under the Companies Act, 1994 vide Registration No. CH-42959(2318)/2001 dated 24 April 2001. The Company started its commercial operation on 01st July, 2003. The Company went for Initial Public Offering (IPO) in 2018. The company is a publicly traded company and is listed with Dhaka Stock Exchange Limited (DSE) and Chittagong Stock Exchanges Limited (CSE) since 10th October, 2018.

1.02 Address of the Registered Office and Factory:

The registered and corporate office of the company is located at House # 65, Road No. 8/A (New), Dhanmondi, Dhaka-1209, Bangladesh.

Factory of the company is situated at 137, Joykrishnapur, Main Road, Maijdee Court, Noakhali.

1.03 Nature of Business:

The Company has engaged in manufacturing and marketing of pharmaceuticals finished products in the categories of Antibiotics, Analgesics, Anti diabetics, Narcotics, Anti pyretic, Anti inflammatory Drugs, Anti ulcerants, Antiemetic, Gastroprokinetic, Anti histamine, Anti spasmodic expectorants, Vitamins & Minerals medicines which is selling mainly in local market.

2.00 Basis of Preparation of Financial Statements

2.01 Basis of Preparation and presentation of Interim Financial Statements

The Financial Statements have been prepared in accordance with the International Financial Reporting Standards (IFRSs) and the International Accounting Standards (IAS) as adopted by the Institute of Chartered Accountants of Bangladesh (ICAB) and subsequently adopted by the Financial Reporting Council, Bangladesh and in compliance with other relevant local laws including the Securities and Exchange Rules, 2020. The presentation of the interim financial statements and the accounting policies used in preparing them are consistent with those of the Annual Financial Statements. Where necessary, the comparatives have been reclassified or extended to take into account any presentational changes made in the Annual Financial Statements. The preparation of the Interim Financial Statements requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities at the date of the Interim Financial Statements. If in the future such estimates and assumptions which are based on management's best judgment at the date of the Interim Financial Statements, deviate from the actual, the original estimates and assumptions will be modified as appropriate in the period in which the circumstances change.

2.02 Statement of Compliance

The Financial Statements have been prepared on accrual basis in accordance with generally accepted accounting principle and practice in Bangladesh in compliance with the Companies Act, 1994, the Bangladesh Securities and Exchange Rules, 2020, The Financial Reporting Act, 2015, the Listing Regulation of Dhaka Stock Exchange Limited (DSE) and Chitagong Stock Exchange Limited (CSE) 2015 and International Financial Reporting Standards (IFRSs) as adopted by the Financial Reporting Council, Bangladesh and other relevant laws and regulations applicable in Bangladesh.

2.03 Application of Standards (IAS's)

As per para 14(2) of the Securities and Exchange Rules 2020, the company have been applied in the preparation of the financial statements for the period from July 2024 to March 2025 with the following International Accounting Standards (IASs) and International Financial Reporting Standards (IFRSs) as adopted by The Financial Reporting Council (FRC), Bangladesh.

Name of the Accounting Standards	Reference No.
International Accounting Standards (IASs)	
Presentation of Financial Statements	IAS-1
Inventories	IAS-2
Statement of Cash Flows	IAS-7
Accounting Policies, Changes in Accounting Estimates and Errors	IAS-8
Events after the Reporting period	IAS-10
Income Taxes	IAS-12
Property, Plant & Equipment	IAS-16
Employee Benefits	IAS-19
The Effects of Changes in Foreign Exchange Rates	IAS-21
Borrowing Costs	IAS-23
Related Party Disclosures	IAS-24
Financial instruments: Presentation	IAS-32
Earnings Per Share	IAS-33
Interim Financial Reporting	IAS-34
Impairment of assets	IAS-36
Provisions, Contingent Liabilities and Contingent Assets	IAS-37
Intangible Assets	IAS-38
International Financial Reporting Standards (IFRSs)	
Financial Instruments: Disclosure	IFRS-7
Operating Segments	IFRS-8
Financial Instruments	IFRS-9
Fair Value Measurement	IFRS-13
Revenue from Contracts with Customers	IFRS-15
Leases	IFRS-16

3.00 Property, Plant and Equipment

31 March, 2026

Particulars	Amount in Taka							Written Down Value as at 31 March, 2026
	Cost			Rate (%)	Depreciation		Balance as on 31 March, 2026	
	Balance as on 01 July, 2025	Addition during the period	Balance as on 31 March, 2026		Balance as on 01 July, 2025	Charge during the period		
Land & Land Development	342,774,940	-	342,774,940	0%	-	-	-	342,774,940
Plant & Machinery	692,749,945	-	692,749,945	10%	478,552,539	16,064,805	494,617,344	198,132,601
Generator	12,396,170	-	12,396,170	10%	10,295,675	157,537	10,453,212	1,942,958
Building Decoration	121,235,416	-	121,235,416	10%	68,129,787	3,982,922	72,112,709	49,122,707
Electrical Installation	39,471,371	-	39,471,371	10%	20,116,570	1,451,610	21,568,180	17,903,191
Gas Installation	389,890	-	389,890	10%	328,474	4,606	333,080	56,810
Office Equipment	58,689,497	111,575	58,801,072	10%	33,830,917	1,869,896	35,700,813	23,100,259
Factory Equipment	64,813,573	-	64,813,573	10%	38,447,733	1,977,438	40,425,171	24,388,402
Furniture and Fixture	49,486,298	-	49,486,298	10%	32,108,029	1,303,370	33,411,399	16,074,899
Vehicle	129,904,291	-	129,904,291	20%	113,425,432	2,471,829	115,897,261	14,007,030
Power House	1,195,705	-	1,195,705	10%	1,016,775	13,420	1,030,195	165,510
Laboratory Equipment	99,725,018	-	99,725,018	10%	48,726,791	3,824,867	52,551,658	47,173,360
Factory Building & Warehouse	424,089,619	-	424,089,619	2.5%	99,539,340	6,085,318	105,624,658	318,464,961
Total as on 31 March, 2026	2,036,921,733	111,575	2,037,033,308		944,518,062	39,207,618	983,725,680	1,053,307,628
Total as on 30 June, 2025	2,036,849,283	72,450	2,036,921,733		886,684,640	57,833,422	944,518,062	1,092,403,671

Allocation of Depreciation	01 July 2025 to 31 March, 2026	01 January 2026 to 31 March, 2026
Charged during the period	39,207,618	13,068,846
Adjustment during the period	-	-
	39,207,618	13,068,846
(a) Depreciation charged to cost of sales (Note-21.00)	36,463,085	12,154,027
(b) Depreciation charged to administrative expenses (Note-22.00)	2,352,457	784,131
(c) Depreciation charged to selling & distribution expenses (Note-23.00)	392,076	130,688
Total	39,207,618	13,068,846

31 March, 2025

Particulars	Amount in Taka							
	Cost			Rate (%)	Depreciation			Written Down Value as at 31 March, 2025
	Balance as on 01 July, 2024	Addition during the period	Balance as on 31 March, 2025		Balance as on 01 July, 2024	Charge during the period	Balance as on 31 March, 2025	
Land & Land Development	342,774,940	-	342,774,940	0%	-	-	-	342,774,940
Plant & Machinery	692,749,945	-	692,749,945	10%	454,752,827	17,849,784	472,602,611	220,147,334
Generator	12,396,170	-	12,396,170	10%	10,062,287	175,041	10,237,328	2,158,842
Building Decoration	121,235,416	-	121,235,416	10%	62,229,162	4,425,469	66,654,631	54,580,785
Electrical Installation	39,471,371	-	39,471,371	10%	17,966,036	1,612,900	19,578,936	19,892,435
Gas Installation	389,890	-	389,890	10%	321,650	5,118	326,768	63,122
Office Equipment	58,689,497	-	58,689,497	10%	31,068,853	2,083,145	33,151,998	25,537,499
Factory Equipment	64,741,123	-	64,741,123	10%	35,526,245	2,206,682	37,732,927	27,008,196
Furniture and Fixture	49,486,298	-	49,486,298	10%	30,177,110	1,452,015	31,629,125	17,857,173
Vehicle	129,904,291	-	129,904,291	20%	109,305,717	3,089,786	112,395,503	17,508,788
Power House	1,195,705	-	1,195,705	10%	996,894	14,911	1,011,805	183,900
Laboratory Equipment	99,725,018	-	99,725,018	10%	43,060,321	4,280,417	47,340,738	52,384,280
Factory Building & Warehouse	424,089,619	-	424,089,619	2.5%	91,217,538	6,241,352	97,458,890	326,630,729
Total as on 31 March, 2025	2,036,849,283	-	2,036,849,283		886,684,640	43,436,620	930,121,260	1,106,728,023

Allocation of Depreciation	01 July 2024 to 31 March, 2025	01 January 2025 to 31 March, 2025
Charged during the period	43,436,620	14,519,909
Adjustment during the period	-	-
	43,436,620	14,519,909
(a) Depreciation charged to cost of sales (Note-21.00)	40,396,057	13,503,516
(b) Depreciation charged to administrative expenses (Note-22.00)	2,606,197	871,194
(c) Depreciation charged to selling & distribution expenses (Note-23.00)	434,366	145,199
Total	43,436,620	14,519,909

3(A) Tax Base Value of Property, Plant and Equipment

31 March, 2026

Particulars	Amount in Taka							Written Down Value as at 31 March, 2026
	Cost			Rate (%)	Depreciation			
	Balance as on 01 July, 2025	Addition during the year	Balance as on 31 March, 2026		Balance as on 01 July, 2025	Charge during the year	Balance as on 31 March, 2026	
Land & Land Development	342,774,940	-	342,774,940	0%	-	-	-	342,774,940
Plant & Machinery	692,749,945	-	692,749,945	20%	610,548,257	12,330,253	622,878,510	69,871,435
Generator	12,396,170	-	12,396,170	20%	12,086,739	46,415	12,133,154	263,016
Building Decoration	121,235,416	-	121,235,416	20%	100,474,460	3,114,143	103,588,603	17,646,813
Electrical Installation	39,471,371	-	39,471,371	20%	31,995,795	1,121,336	33,117,131	6,354,240
Gas Installation	389,890	-	389,890	20%	381,952	1,191	383,143	6,747
Office Equipment	61,986,517	111,575	62,098,092	20%	49,932,375	1,824,858	51,757,233	10,340,859
Factory Equipment	64,813,573	-	64,813,573	10%	39,936,891	1,865,751	41,802,642	23,010,931
Furniture and Fixture	49,486,298	-	49,486,298	10%	32,949,968	1,240,225	34,190,193	15,296,105
Vehicle	129,904,291	-	129,904,291	20%	115,421,213	2,172,462	117,593,675	12,310,616
Power House	1,195,705	-	1,195,705	20%	1,170,636	3,760	1,174,396	21,309
Laboratory Equipment	99,725,018	-	99,725,018	20%	74,546,085	3,776,840	78,322,925	21,402,093
Factory Building & Warehouse	424,089,619	-	424,089,619	10%	282,299,858	10,634,232	292,934,090	131,155,529
Total as on 31 March, 2026	2,040,218,753	111,575	2,040,330,328		1,351,744,229	38,131,466	1,389,875,695	650,454,633
Total as on 30 June, 2025	2,038,758,503	1,460,250	2,040,218,753		1,290,764,161	60,980,068	1,351,744,229	688,474,524

31 March, 2025

Particulars	Amount in Taka							Written Down Value as at 31 March, 2025
	Cost			Rate (%)	Depreciation			
	Balance as on 01 July, 2024	Addition during the year	Balance as on 31 March, 2025		Balance as on 01 July, 2024	Charge during the year	Balance as on 31 March, 2025	
Land & Land Development	342,774,940	-	342,774,940	0%	-	-	-	342,774,940
Plant & Machinery	692,749,945	-	692,749,945	10%	589,997,835	15,412,817	605,410,652	87,339,293
Generator	12,396,170	-	12,396,170	10%	12,009,381	58,018	12,067,399	328,771
Building Decoration	121,235,416	-	121,235,416	10%	95,284,221	3,892,679	99,176,900	22,058,516
Electrical Installation	39,471,371	-	39,471,371	10%	30,126,901	1,401,671	31,528,572	7,942,799
Gas Installation	389,890	-	389,890	10%	379,967	1,488	381,455	8,435
Office Equipment	60,598,717	-	60,598,717	10%	46,918,839	2,051,982	48,970,821	11,627,896
Factory Equipment	64,741,123	-	64,741,123	10%	37,172,815	2,067,623	39,240,438	25,500,685
Furniture and Fixture	49,486,298	-	49,486,298	10%	31,112,598	1,378,028	32,490,626	16,995,672
Vehicle	129,904,291	-	129,904,291	20%	111,800,443	2,715,577	114,516,020	15,388,271
Power House	1,195,705	-	1,195,705	10%	1,164,369	4,700	1,169,069	26,636
Laboratory Equipment	99,725,018	-	99,725,018	10%	68,251,352	4,721,050	72,972,402	26,752,616
Factory Building & Warehouse	424,089,619	-	424,089,619	2.5%	266,545,440	11,815,813	278,361,253	145,728,366
Total as on 31 March, 2025	2,038,758,503	-	2,038,758,503		1,290,764,161	45,521,446	1,336,285,607	702,472,896

4.00 Intangible Assets

31 March, 2026

Particulars	Cost			Rate (%)	Amortization			Written Down Value as at 31 March, 2026
	Balance as on 01 July, 2025	Addition during the period	Balance as on 31 March, 2026		Balance as on 01 July, 2025	Charge during the period	Balance as on 31 March, 2026	
Software	3,297,020	-	3,297,020	10%	875,485	181,615	1,057,100	2,239,920
Total as on 31 March, 2026	3,297,020	-	3,297,020		875,485	181,615	1,057,100	2,239,920
Total as on 30 June, 2025	1,909,220	1,387,800	3,297,020		684,582	190,903	875,485	2,421,535

Allocation of Amortization	01 July 2025 to 31 March, 2026	01 January 2026 to 31 March, 2026
Charged during the period	181,615	60,538
Adjustment during the period	-	-
	181,615	60,538
Amortization charged to administrative expenses (Note-22.00)	181,615	60,538
Total	181,615	60,538

31 March, 2025

Particulars	Cost			Rate (%)	Amortization			Written Down Value as at 31 March, 2025
	Balance as on 01 July, 2024	Addition during the period	Balance as on 31 March, 2025		Balance as on 01 July, 2024	Charge during the period	Balance as on 31 March, 2025	
Software	1,909,220	-	1,909,220	10%	684,582	91,848	776,430	1,132,790
Total as on 31 March, 2025	1,909,220	-	1,909,220		684,582	91,848	776,430	1,132,790

Allocation of Amortization	01 July 2024 to 31 March, 2025	01 January 2025 to 31 March, 2025
Charged during the period	91,848	30,616
Adjustment during the period	-	-
	91,848	30,616
Amortization charged to administrative expenses (Note-22.00)	91,848	30,616
Total	91,848	30,616

5.00 Right of Use Assets (RoU)

Right-of-use assets (ROU) arise due to implementation of IFRS 16 from 1st July 2019. This is made up from use of building as lease of Corporate Office, Factory and Depot offices.

31 March, 2026

Particulars	Cost			Depreciation			Written Down Value as at 31 March, 2026
	Balance as on 01 July, 2025	Addition during the period	Balance as on 31 March, 2026	Balance as on 01 July, 2025	Charge during the period	Balance as on 31 March, 2026	
Right of Use Assets (RoU)	26,266,197	-	26,266,197	21,889,034	927,306	22,816,340	3,449,857
Total as on 31 March, 2026	26,266,197	-	26,266,197	21,889,034	927,306	22,816,340	3,449,857
Total as on 30 June, 2025	26,266,197	-	26,266,197	20,614,235	1,274,799	21,889,034	4,377,163

Allocation of Depreciation	01 July 2025 to 31 March, 2026	01 January 2026 to 31 March, 2026
Charged during the period	927,306	316,057
Adjustment during the period	-	-
	927,306	316,057
Depreciation charged to administrative expenses (Note-22.00)	927,306	316,057
Total	927,306	316,057

31 March, 2025

Particulars	Cost			Depreciation			Written Down Value as at 31 March, 2025
	Balance as on 01 July, 2024	Addition during the period	Balance as on 31 March, 2025	Balance as on 01 July, 2024	Charge during the period	Balance as on 31 March, 2025	
Right of Use Assets (RoU)	26,266,197	-	26,266,197	20,614,235	979,299	21,593,534	4,672,663
Total as on 31 March, 2025	26,266,197	-	26,266,197	20,614,235	979,299	21,593,534	4,672,663

Allocation of Depreciation	01 July 2024 to 31 March, 2025	01 January 2025 to 31 March, 2025
Charged during the period	979,299	322,950
Adjustment during the period	-	-
	979,299	322,950
Depreciation charged to administrative expenses (Note-22.00)	979,299	322,950
Total	979,299	322,950

Amount in Taka	
31-Mar-26	30-Jun-25

6.00 Capital Work in Progress

A) Construction work-in-progress (Building)

Opening Balance	323,279,938	317,671,463
Addition during the period	1,579,940	5,608,475
Transfer to Property, Plant and equipment	-	-
Closing Balance	324,859,878	323,279,938

B) Plant and Machinery in transit and installation

Opening Balance	-	-
Addition during the period	-	-
Transfer to Property, Plant and equipment	-	-
Closing Balance	-	-
Total Closing Balance	324,859,878	323,279,938

A new building is being constructed in the factory premises located at Binodpur, Sadar, Noakhali to increase the overall production capacity of The Silva Pharmaceuticals Limited which have not started commercial production yet.

7.00 Inventories

Raw Materials	255,928,203	256,370,266
Packing Materials	29,227,452	36,672,514
Spares & Tools	5,875,468	10,758,465
Promotional Materials & Gift items	13,926,351	16,895,726
Finished goods	95,388,586	105,874,652
Work in Process-Closing	6,600,248	16,439,992
Total	406,946,308	443,011,615

8.00 Trade and Other Receivable

Particulars

Trade Receivables	194,346,903	229,474,561
Accrued Interest	-	143,437
Closing Balance:	194,346,903	229,617,998

Trade receivables occurred in the ordinary course of business and are unsecured but considered good and recoverable within six months. The Accounts Receivables have no securities except their personal securities.

There was no amount due by the Directors (including Managing Director, Managing Agent, Manager and other Officers of the company) and any of them severally or jointly with any other person(s).

There was also no other amount due by associate undertakings.

Amount in Taka	
31-Mar-26	30-Jun-25

9.00 Advances, Deposits & Prepayments

Advances & Prepayments

Advance Income Tax	7,967,561	5,060,573
Advance against Purchase	25,246,855	21,987,968
Advance against L/C	9,846,752	9,756,116
Advance against Travelling & Others	4,281,572	2,640,738
Advance against Motor-cycle Expenses	3,864,715	4,210,305
Advance against Employee	2,794,873	1,853,740
Advance against Depot Rent	1,902,600	1,905,600
Prepayments of VAT	6,658,712	6,612,456
Total:	62,563,640	54,027,496

Deposits

Security Deposit

Bakhrabad Gas System Ltd	48,610	48,610
Bangladesh T & T Board	40,600	40,600
Power Development Board	288,000	288,000
Total:	377,210	377,210
Total:	62,940,850	54,404,706

Advances: These advances are un-secured but good and subsequently realized and/or adjusted.

Deposits: These balances represents security deposits made by the company for Gas connection, Telephone line connection & Electricity connection etc.

There is no claim against the company, which can be acknowledge as debt.

There is no aggregate amount due from the Directors (including Managing Director) and managing agents of the company and any of them severally or jointly with any other person.

10.00 Fixed Deposits Receipts (FDR)

Dutch Bangla Bank Ltd. Satmasjid Road branch	-	-
Shahjalal Islami Bank Ltd. Satmosjid Road Branch, Dhaka (Short Term Investment)	-	64,030,846
Total	-	64,030,846

11.00 Cash and Cash Equivalents

Cash in Hand at factory	1,512	5,670
Cash in Hand at Head Office	16,012	10,057
Cash in Hand at Depot Office	25,397,897	20,011,676
Postal Imprest	3,065	3,065
Cash at Bank	58,377,144	18,742,881
Total:	83,795,630	38,773,349

12.00 Share Capital:

12.01 Authorized Share Capital :

15,00,00,000 ordinary shares of Tk 10/= each	1,500,000,000	1,500,000,000
--	----------------------	----------------------

Amount in Taka	
31-Mar-26	30-Jun-25

12.02 Issued, subscribed and paid-up share capital:

(a) By Cash	1,300,000,000	1,300,000,000
130,000,000 Ordinary shares of Tk. 10/- each fully paid in cash		
(b) By Issue of Bonus Share	65,000,000	65,000,000
6,500,000 Ordinary shares of Tk. 10/- each fully paid-up as bonus shares		
Total 13,65,00,000 ordinary shares of Taka 10/= each.	1,365,000,000	1,365,000,000

The Composition of Shareholdings of Ordinary Shares of the company is shown below:

Category of Shareholders	31-Mar-26		30-Jun-25	
	No. of Shares	%	No. of Shares	%
Directors/Sponsors	61,716,452	45.21%	61,716,452	45.21%
Financial and other Institutions	24,745,635	18.13%	22,990,859	16.84%
Foreign	11,025	0.01%	11,025	0.01%
General Public	50,026,888	36.65%	51,781,664	37.94%
Total	136,500,000	100.00%	136,500,000	100.00%

13.00 Retained Earnings

Opening balance	748,040,947	890,949,495
Dividend Paid	-	(9,957,150)
Net profit after tax during the period	(98,913,321)	(132,951,398)
Closing Balance:	649,127,626	748,040,947

14.00 Deferred Tax Liability

Deferred tax assets and liabilities have been recognised and measured in accordance with the provision of IAS 12 "Income Taxes". Related deferred tax expenses/income have been disclosed in note 27.02. The components of deferred tax assets and liabilities are given below:

Particulars	Carrying Amount	Tax base value (*)	Taxable (Deductible) Temporary Difference	Applicable tax rate	Deferred tax Liability
31 March, 2026					
Property, Plant and Equipment	1,055,547,548	650,454,633	405,092,915	20.00%	81,018,583
Total deferred tax liabilities as on 31 March, 2026	1,055,547,548	650,454,633	405,092,915		81,018,583
Total as on 30 June, 2025					
Property, Plant and Equipment	1,094,825,206	688,474,524	406,350,682	20.00%	81,270,136
Total deferred tax liabilities as on 30 June 2025	1,094,825,206	688,474,524	406,350,682		81,270,136

(*) The schedule of Tax base value of Property Plant and equipment are shown in Note 03(A) in this financial statements.

15.00 Lease Liability

Opening Balance	3,377,163	4,617,962
Addition during the period	-	-
Finance Charge	267,984	454,922
Paid during the Period	(1,195,290)	(1,695,721)
Closing Balance	2,449,857	3,377,163
Transferred to Current Maturity	(1,013,734)	(1,066,472)
Non-Current Portion	1,436,123	2,310,691

		Amount in Taka	
		31-Mar-26	30-Jun-25
16.00 Trade and Other Payables			
Trade Payable		14,305,023	9,971,279
This represents the amount payable to suppliers of raw materials, packing materials, etc. All suppliers were paid on a regular basis.			
17.00 Unclaimed Dividend			
For the year 2023-2024		35,347	35,347
For the year 2022-2023		49,203	49,203
For the year 2021-2022		-	39,875
Interest (net off AIT & Bank charge)		12,144	14,733
Total		96,694	139,158
NB: During this period the Unclaimed Cash Dividend for the year 2021-2022 Tk. 39,875.00 transferred to the Capital Market Stabilization Fund (CMSF).			
18.00 Short Term Finance			
SJIBL-BAI-MUAZZAL (FO)		-	12,912,624
DBBL, Account No. 1714050001188		-	15,307,113
Total		-	28,219,737
19.00 Provision for expenses			
Accrued Expenses		7,516,777	6,451,745
Audit & Professional Fees		2,634,125	3,380,750
Worker's Profit Participation Fund (WPPF)	Note- 19.01	-	-
Provision for Income Tax	Note- 19.02	9,738,289	6,469,906
Total		19,889,191	16,302,401
19.01 Worker's Profit Participation Fund (WPPF)			
Opening balance		-	2,518,229
Provision made during the period		-	-
Total		-	2,518,229
Paid during the year		-	(2,518,229)
Closing balance		-	-
19.02 Provision for Income Tax			
Opening balance		6,469,906	5,445,728
Provision made during the period		3,268,383	12,780,824
Total		9,738,289	18,226,552
Paid/Adjustment made during the period		-	(11,756,646)
Closing balance		9,738,289	6,469,906

<i>Amount in Taka</i>				
<i>Third Quarter ended Results</i>		<i>Quarterly Results</i>		
01/07/2025 to 31/03/2026	01/07/2024 to 31/03/2025	01/01/2026 to 31/03/2026	01/01/2025 to 31/03/2025	
20.00 Revenue				
Local Sales (Net)	255,260,286	309,278,213	80,286,379	107,643,330
Total:	255,260,286	309,278,213	80,286,379	107,643,330
21.00 Cost of goods sold				
Raw materials consumed	64,765,666	91,888,502	20,362,808	35,710,191
Packing materials consumed	22,801,053	32,263,158	4,193,758	7,756,690
Consumable item consumed	5,086,815	8,374,250	104,736	1,737,723
	92,653,534	132,525,910	24,661,302	45,204,604
Work in process- Opening	16,439,992	6,361,728	2,590,244	6,394,273
Work in process- Closing	(6,600,248)	(6,412,482)	(6,600,248)	(6,412,482)
Change in work in process	9,839,744	(50,754)	(4,010,004)	(18,209)
Total consumption	102,493,278	132,475,156	20,651,298	45,186,395
Manufacturing Overhead	23,870,625	26,691,364	8,849,100	8,887,242
Depreciation	36,463,085	40,396,057	12,154,027	13,503,516
Cost of production	162,826,988	199,562,577	41,654,425	67,577,153
Finished goods - Opening	105,874,652	109,462,185	100,475,400	97,863,425
Finished goods - Closing	(95,388,586)	(97,524,876)	(95,388,586)	(97,524,876)
Change of finished goods stock	10,486,066	11,937,309	5,086,814	338,549
Cost of Physician Sample	(4,123,796)	(3,446,109)	(696,063)	(1,407,862)
Cost of Goods Sold	169,189,258	208,053,777	46,045,176	66,507,840
21.01 Manufacturing overhead				
Salary, Wages & Allowances	14,399,204	14,931,205	5,161,275	4,932,617
Workers' benefit and welfare expense	817,895	1,024,685	455,866	435,074
Overtime	205,102	312,837	63,425	116,641
Staff Welfare Expenses	428,734	364,483	143,772	119,127
Laboratory Expenses	23,580	102,938	23,580	26,340
Postage & Stamp	33,957	19,726	14,410	7,587
Indirect materials	86,534	379,745	86,534	8,162
Electricity Bill	2,513,799	2,784,818	705,465	848,194
Gas & Water bill	152,919	177,502	49,254	59,896
Uniform and liveries	76,815	-	12,915	-
Carriage Inward	206,373	413,224	33,000	103,590
Power & Fuel	117,745	106,601	25,375	54,019
Printing & Stationery	114,484	442,447	14,010	244,599
Traveling & Conveyance	118,733	65,462	64,875	18,675
Factory Rent	1,260,000	1,080,000	420,000	360,000
Toll Charges	2,576,074	3,382,158	1,052,663	1,292,778
Repairs & Maintenance	582,806	829,033	485,435	181,531
Sanitation & Cleaning	41,476	45,031	15,246	36,090
Entertainment	114,395	229,469	22,000	42,322
Total	23,870,625	26,691,364	8,849,100	8,887,242

<i>Amount in Taka</i>			
<i>Third Quarter ended Results</i>		<i>Quarterly Results</i>	
01/07/2025 to 31/03/2026	01/07/2024 to 31/03/2025	01/01/2026 to 31/03/2026	01/01/2025 to 31/03/2025

22.00 Administrative Expenses

Salary, Wages & Allowances	20,051,906	19,745,655	8,015,376	6,336,933
Staff Welfare expenses	662,351	784,675	211,747	303,186
Printing & Stationery	32,119	151,409	7,400	77,564
Phone, Fax, Mobile and Internet Bill	365,963	432,246	91,135	-
Postage & Stamps	44,307	51,779	7,935	20,760
Traveling & Conveyance	906,747	652,869	89,759	77,748
Utility Bill	775,140	671,439	165,276	161,480
Entertainment	207,368	351,628	35,519	88,640
Donation and Subscription	215,330	125,400	118,099	-
Licenses Renewal and Registration Fee	231,840	97,980	29,200	19,780
Audit Fees	301,875	301,875	100,625	100,625
Directors Remuneration	-	500,000	-	-
Board meeting attending fees	243,750	253,125	93,750	65,625
Amortization of Intangible Assets	181,615	91,848	60,538	30,616
Depreciation of Right-of-use Assets	927,306	979,299	316,057	322,950
Depreciation	2,352,457	2,606,197	784,018	871,194
Repairs & Maintenance	1,297,315	779,083	901,710	207,353
RJSC Exp.	38,141	6,188	38,141	6,188
Meeting & Conference Expenses	576,277	464,998	-	-
Legal & Professional fees	1,950,615	2,307,310	1,403,425	1,492,000
Total	31,362,422	31,355,003	12,469,710	10,182,642

23.00 Selling & Distribution Expenses

Salary, Wages & Allowances	88,481,858	103,079,258	31,182,148	35,016,034
Field forces expenses	24,661,470	18,135,215	4,637,186	5,639,781
Transportation & Handling Expenses	6,941,146	2,986,411	2,293,639	917,219
Staff Welfare expenses	1,057,689	1,475,801	311,704	310,172
Business Promotion Expenses	2,583,957	1,103,326	520,957	482,435
Repair & Maintenance	430,875	573,226	95,675	193,038
Traveling and conveyance Expenses	1,981,115	1,613,436	518,473	445,118
Water, electricity and Gas	786,944	413,903	327,592	118,549
Phone, Fax and Mobile Bill	294,460	158,442	77,550	33,540
Sample Expenses	4,123,796	3,446,109	696,063	1,407,862
Consumption of promotional materials	5,485,360	3,169,559	1,076,691	1,203,461
Postage & Courier	854,406	777,373	319,355	214,380
Entertainment	208,285	229,434	66,765	75,418
Printing & Stationery	651,254	1,226,093	164,328	350,080
Depot Rent	3,140,898	3,083,000	964,138	905,900
Product Development Expenses	55,864	54,500	55,864	-
Training Expenses	171,290	774,846	2,930	56,669
Bank Charge	500,841	396,455	330,648	116,350
Depreciation	392,076	434,366	130,669	145,199
Vehicle Maintenance	1,251,003	1,526,444	336,697	324,882
Loading & Unloading	123,662	221,167	41,351	66,454
License fees & Renewals	182,720	167,911	15,120	30,930
Incentive & Award Expenses	6,360,955	-	4,658,385	-
Total	150,721,924	145,046,275	48,823,928	48,053,471

24.00 Financial Expenses

Interest on Short Term Loan	2,416,672	3,141,651	35,026	1,460,003
Bank Charge & Commission	71,356	12,177	11,356	-
Finance Charges for lease	267,984	351,992	82,374	109,480
Total	2,756,012	3,505,820	128,756	1,569,483

<i>Amount in Taka</i>			
<i>Third Quarter ended Results</i>		<i>Quarterly Results</i>	
01/07/2025 to 31/03/2026	01/07/2024 to 31/03/2025	01/01/2026 to 31/03/2026	01/01/2025 to 31/03/2025

25.00 Other Income

Interest on FDR	2,721,696	4,486,952	572,124	1,418,840
Interest on Bank STD Accounts	16,250	4,337	-	1,951
Miscellaneous Income	134,893	480,455	72,458	185,460
	2,872,839	4,971,744	644,582	1,606,251

26.00 Workers Profit Participation and Welfare Fund (WPP&WF)

Net Profit before Contribution to WPPF&WF	(95,896,491)	(73,710,918)	(26,536,609)	(17,063,855)
Rate of contribution to WPPF(%)	5.00%	5.00%	5.00%	5.00%

Workers Profit Participation and Welfare Fund (WPPF&WF) - - - -

Note: Allocation for workers' profit participation fund has been made @ 5% of profit after charging such expenses as per provisions of the Bangladesh Labour Act, 2006 (Amendment 2013).

27.00 Income Tax expenses:

27.01 Current Tax Expenses

Net Profit before Income Tax	(95,896,491)	(73,710,918)	(26,536,609)	(17,063,855)
Accounting Depreciation	39,389,233	43,528,468	13,129,252	14,550,525
Tax Depreciation	(38,131,466)	(45,521,446)	(12,710,487)	(15,173,814)
Taxable Profit	(94,638,724)	(75,703,896)	(26,117,844)	(17,687,144)
Tax Rate	20.00%	20.00%	20.00%	20.00%
Current Tax Expenses during the period	(18,927,745)	(15,140,779)	(5,223,543)	(3,537,430)
Current Tax Expenses for the previous Assessment year	-	-	-	-
Total Current Tax Expenses	(18,927,745)	(15,140,779)	(5,223,543)	(3,537,430)

Minimum Tax Calculation

Calculation of Gross Receipts

Revenue from net sales	255,260,286	309,278,213	80,286,379	107,643,330
Other Income				
Interest on FDR	2,721,696	4,486,952	572,124	1,418,840
Interest on Bank deposit	16,250	4,337	-	1,951
Other Income	134,893	480,455	72,458	185,460
Total Gross Receipts	258,133,125	314,249,957	80,930,961	109,249,581
Minimum Tax (1.00% on gross receipts except Interest income)	2,553,952	1,858,552	803,589	646,973
AIT paid on Interest income and Vehicle (As minimum Tax)	714,431	1,708,793	164,680	805,040
Total Minimum Tax	3,268,383	3,567,345	968,269	1,452,013
Income Tax Provision whichever is higher	3,268,383	3,567,345	968,269	1,452,013

The income tax provision has been made based on the higher of the regular tax on taxable income and minimum tax on gross receipts as per Section 163(6) of the Income Tax Act, 2023. Since the minimum tax exceeds the regular tax liability, provision has been made accordingly.

27.02 Deferred Tax Expenses/(Income)

Closing balance of deferred tax liability	Note- 14	81,018,583	81,077,583	81,018,583	81,077,583
Opening balance of deferred tax liability	Note- 14	(81,270,136)	(80,678,988)	(81,102,362)	(80,952,926)
Deferred Tax Expenses/(Income)		(251,553)	398,595	(83,779)	124,657

28.00 Earnings per Share

Net profit after Tax (Numerator)	(98,913,321)	(77,676,858)	(27,421,099)	(18,640,525)
Number of Ordinary Shares (Denominator)	136,500,000	136,500,000	136,500,000	136,500,000
Basic Earnings per Share (EPS)	(0.72)	(0.57)	(0.20)	(0.14)

There is no potential dilutive claim during the period. Hence no diluted EPS has been calculated during the reporting period.

	<i>Amount in Taka</i>	
	31-Mar-26	30-Jun-25
29.00 Net Asset Value (NAV) Per Share		
Total Assets	2,131,886,974	2,252,320,821
Less: Total Liabilities	117,759,348	139,279,874
Net Asset Value	2,014,127,626	2,113,040,947
Total Number of Share outstanding	136,500,000	136,500,000
Net Asset Value (NAV) Per Share	14.76	15.48
30.00 Cash received from Customers	01/07/2025 to 31/03/2026	01/07/2024 to 31/03/2025
Sales during the year	255,260,286	309,278,213
Opening Trade Receivable	229,474,561	255,718,828
Closing Trade Receivable	(194,346,903)	(245,988,482)
Total Cash Received from Customers	290,387,944	319,008,559
31.00 Cash received from non-operating income		
Other income	2,872,839	4,971,744
Opening interest receivable	143,437	411,593
Closing interest receivable	-	(973,361)
Total Cash received from non-operating income	3,016,276	4,409,976
32.00 Cash Paid to Suppliers		
Purchase (Raw, Packing, Promotional, Indirect material and Spare parts)	82,485,931	101,396,970
Opening Accounts Payable	9,971,279	7,162,713
Closing Accounts Payable	(14,305,023)	(8,335,307)
Closing Advance against Purchase & L/C	35,093,607	26,613,205
Opening Advance against Purchase & L/C	(31,744,084)	(33,375,077)
Total Cash Paid to Suppliers	81,501,710	93,462,504
33.00 Cash Paid to Employees		
Salary, Wages & Allowances including contribution to PF	125,081,742	140,381,077
Workers' benefit and welfare expense	817,895	1,024,685
Overtime	205,102	312,837
Directors Remuneration	-	500,000
Board meeting attending fees	243,750	253,125
Field forces expenses	24,661,470	18,135,215
Worker's Profit Participation and Welfare Fund	-	-
Opening Payable	5,986,548	8,429,371
Closing Payable	(7,076,586)	(8,040,918)
Closing Advance to Employee	2,794,873	2,460,874
Opening Advance to Employee	(1,853,740)	(1,973,449)
Total Cash Paid to Employees	150,861,054	161,482,817

34.00 Cash Paid for Others

Manufacturing Overhead (excluding pay to employee & Supplier)	7,933,156	9,678,409
Administrative Overhead (excluding Depreciation & pay to employee)	6,943,037	6,394,204
Selling and Distribution overhead (excluding sample, promotional, Depreciation & pay to employee)	26,519,675	15,305,967
Opening Liabilities for Expenses	3,845,947	4,058,407
Closing Liabilities for Expenses	(3,074,316)	(5,994,821)
Closing Advance deposit & prepayment	17,084,809	13,062,495
Opening Advance deposit & prepayment	(15,746,309)	(15,583,921)
Total Cash Paid for Others	43,505,999	26,920,740

35.00 Income Tax paid

Advance Income Tax paid	2,906,988	2,336,308
Total Income Tax paid	2,906,988	2,336,308

36.00 Cash payment for Acquisition of Property, Plant and Equipment (PPE)

Property, Plant and Equipment addition during the year	111,575	-
Addition from Intangible Assets	-	-
Addition from Capital Work-in-Progress	-	-
Total Cash payment for Acquisition PPE	111,575	-

37.00 Net Operating Cash Flow Per Share(NOCFPS)

Net Operating Cash Flow	12,140,441	36,062,338
Weighted Average Number of Ordinary Shares (Denominator)	136,500,000	136,500,000
Net Operating Cash Flow Per Share(NOCFPS)	0.09	0.26

38.00 Disclosure as per requirement of the Companies Act, 1994

38.01 Disclosure as per Schedule XI, part I, para 4 of the Companies Act, 1994 are given below:

Sl. No.	Particulars	31-Mar-26	30-Jun-25
		Amount in Taka	
I	Receivables considered good and in respect of which the company is fully secured.	-	-
II	Receivables considered good for which the company holds no security other than the debtor's personal security.	194,346,903	229,474,561
III	Receivables considered doubtful or bad.	-	-
IV	Receivables due by directors or other officers of the company or any of them either severally or jointly with any other person or receivables due by firms or private companies respectively in which any director is a partner or a director or a member.	-	-
V	Receivables due by companies under the same management.	-	-
VI	The maximum amount due by directors or other officers of the company at any time during the year.	-	-
Total:		194,346,903	229,474,561

38.02 Disclosure as per Schedule XI, part I, para 6 of the Companies Act, 1994 are given below:

Sl. No.	Particulars	31-Mar-26	30-Jun-25
		Amount in Taka	
I	Advances, Deposits and Prepayments considered good and in respect of which the company is fully secured.	-	-
II	Advances, Deposits and Prepayments considered good for which the company holds no security.	51,999,690	45,699,923
III	Advances, Deposits and Prepayments considered doubtful or bad.	-	-
IV	Advances, Deposits and Prepayments due by directors or other officers of the company or any of them either severally or jointly with any other person or Advance, Deposits and Prepayment due by firms or private companies respectively in which any director is a partner or a director or a member.	-	-
V	Advance, Deposits and Prepayment due by companies under the same management.	-	-
VI	The maximum amount due by directors or other officers of the company at any time during the year.	10,941,160	8,704,783
Total:		62,940,850	54,404,706

38.03 Disclosure of Schedule XI, Part II, Para 3, of the Companies Act, 1994 are given below:

I. a. Turnover:

Particulars	01/07/2025 to 31/03/2026	
	Quantity (Pcs/PHs)	Amount in Taka
Tablet	41,582,746	174,917,481
Capsule	3,236,354	27,755,794
Liquid	570,483	45,367,181
Dry Syrup	82,870	7,219,830
Total	45,472,453	255,260,286

b. No Commission paid to selling agents during the period.

c. No brokerage and discount paid on sales, other than the usual trade discount during the period.

d. (i) Raw Materials consumed:

Particulars	01/07/2025 to 31/03/2026	
	Quantity (KG)	Amount in Taka
Opening stock	158,299	256,370,266
Purchase	33,238	64,323,603
Raw material available for consumption	191,537	320,693,869
Closing stock	(109,448)	(255,928,203)
Total Raw material consumed	82,089	64,765,666

(ii) Finished goods:

Particulars	01/07/2025 to 31/03/2026		
	Opening Qty.	Production Qty.	Closing Qty.
Tablet (Pcs.)	13,311,461	41,235,000	12,963,715
Capsule (Pcs.)	4,442,518	3,450,000	4,656,164
Liquid (PHs.)	143,454	575,000	147,971
Dry Syrup (PHs.)	42,850	90,000	49,980
Total	17,940,283	45,350,000	17,817,830

ii. Disclosure as per requirement of Schedule XI, Part II, Note-5 of Para 3, of the Companies Act, 1994 are given below:**Employee Position of SILVA PHARMACEUTICALS LTD. as at 31 March, 2026**

Salary Range (Monthly)	Total Employee	Officer & Staff		Worker & Employee	
		Head Office	Factory	Field	Factory
Number of Employees whose salary below taka 3,000 or 5,500 p.m.	-	-	-	-	-
Number of Employees whose salary above taka 3,000 or 5,500 p.m.	678	50	19	513	96
Total	678	50	19	513	96

38.04 Disclosure as per requirement of schedule XI, part II, Para 4 are given below:

01 July 2025 to 31 March, 2026

- | | |
|--|---------|
| (a) Managerial Remuneration paid or payable during the financial period to the directors, including managing directors, a managing agent or manager; | Nil |
| (b) Expenses re-imbursed to the Managing Agent; | Nil |
| (c) Commission or Other Remuneration payable separately to a managing agent or his associate; | Nil |
| (d) Commission received or receivable by the managing agent or his associate as selling or buying agent of other concerns in respect of contracts entered into by such concerns with the company.; | Nil |
| (e) The money value of the contracts for the sale or purchase of goods and materials or supply of services, entered into by the company with the managing agent or his associate during the financial period.; | Nil |
| (f) Any other perquisite or benefits in cash or in kind stating, approximate money value where practicable ; | 243,750 |
| (g) Other allowances and commission including guarantee commission. | Nil |
| (h) Pensions etc. | |
| (i) Pensions | Nil |
| (ii) Gratuities | Nil |
| (iii) Payments from a provident funds, in excess of own subscription and interest thereon | Nil |
| (iv) Compensation for loss of office | Nil |
| (v) Consideration in connection with retirement from office. | Nil |

38.05 Disclosure as per requirement of schedule XI, Part II, Para 7 are given below:

Capacity utilization of SILVA PHARMACEUTICALS LTD. For the period ended 31 March, 2026

Name of Item	Production Capacity	Actual Production	% of Capacity Utilization
	Million Pcs/Ph.	Million Pcs/Ph.	
Tablet	150	41.24	27.49%
Capsule	43.50	3.45	7.93%
Liquid	1.5	0.58	38.33%
Dry Syrup	1.35	0.09	6.67%
Total	195.225	45.35	23.23%

38.06 Disclosure as per requirement of schedule XI, part II, Para 8 are given below:

- a) **Value of imports** calculated on C.I.F basis by the company during the financial period ended 31 March, 2026 in respect of Raw materials, Component and Spare parts and Capital Goods were as follows:

Sl. No.	Particulars	Import		
		Unit	Quantity	Amount in BDT
i	Raw Materials	Kg/Ltr.	575	4,848,787
ii	Packing Materials	Pcs/Kg	6,043	3,646,585
iii	Components and Spare parts	Set	-	-
iv	Capital Goods	Set/Unit	-	-
	Total		6,618	8,495,372

- b) The Company did not have any expenditure in foreign currency during the period on account of Royalty, Know-how, Professional consultation fees, Interest and other matters.
- c) Value of all imported raw materials, spare parts and components consumed during the financial period and the value of all indigenous raw materials, spare parts and components similarly **consumed** and the percentage of each to the total consumption were as follows:

Particulars	Imported Value (in BDT)	Imported in percentage (%)	Indigenous Value (in BDT)	Indigenous in percentage(%)	Total
Raw Materials	5,887,523	9.09%	58,878,143	90.91%	64,765,666
Packing Materials	3,569,082	15.65%	19,231,971	84.35%	22,801,053
Components and Spare parts	-	0.00%	5,086,815	100.00%	5,086,815
Total	9,456,605	10.21%	83,196,929	89.79%	92,653,534

- d) No amount has been remitted during the period in foreign currencies on account of dividends for non-residents shareholders,
- e) Earnings in foreign exchange classified under the following heads as follows:
- i) No export made during the period;
 - ii) No royalty , know -how, professional and consultation fees were received;
 - iii) No Interest and Dividend received;
 - iv) No Other income received

39.00 Reconciliation of Net income with Cash Flows from Operating Activities

Particulars	01/07/2025 to 31/03/2026	01/07/2024 to 31/03/2025
Net Profit before Income tax	(95,896,491)	(73,710,918)
<u>Adjustment for:</u>		
Depreciation	40,134,924	44,415,919
Amortization	181,615	91,848
Finance Expense for lease	267,984	351,992
	40,584,523	44,859,759
Decrease (Increase) in Advances, deposits & Prepayments.	(5,629,156)	8,795,873
Decrease (Increase) in Trade & Other Receivable	35,271,095	9,168,578
Increase (Decrease) in Accounts and Other Payable	4,333,744	1,172,594
Increase (Decrease) in Provision and Accruals	318,407	1,547,961
Decrease (Increase) in Inventories	36,065,307	46,564,799
Income Tax Paid	(2,906,988)	(2,336,308)
Net Cash Generated From Operating activities (indirect method)	12,140,441	36,062,338
Net Cash Generated From Operating activities (Direct method)	12,140,441	36,062,338

40.00 Disclosures as per IAS 24 Related Party disclosures are as follows:

The company carried out a number of transaction with related parties. The following are the related parties transactions of Silva pharmaceuticals Limited has been disclosed as required by IAS 24 Related Party Disclosures:

40.01 Disclosures as per paragraph 17 of IAS 24 are as follows:

(a) Short term employee benefits:

Name of the Related Parties	Nature of Relationship	Nature of Transaction	Value of goods / Services received during the period	Balance payable as on 31.03.2026
Mrs. Silvana Mirza	Chairman	Board Meeting Fees	28,125	-
Mrs. Samina Mirza	Director	Board Meeting Fees	18,750	-
Mrs. Farhana Mirza	Director	Board Meeting Fees	-	-
Md. Monsur Rahman (Representative of Adarsha Fisheries & Poultry Farms Ltd.)	Director	Board, AC & NRC Meeting Fees	65,625	-
AKM Nuruzzaman (Representative of ICB)	Director	Board Meeting Fees	18,750	-
ATM Sarrowar Kamal Chowdhury	Independent Director	Board, AC & NRC Meeting Fees	65,625	-
Muhammad Moniruzzaman, FCA	Independent Director	Board, AC & NRC Meeting Fees	46,875	-
Mr. A. R. Hassan Mirza	Executive Director & Sponsor Shareholder	Salary & Allowances	2,700,000	300,000
		Office Rent	1,195,290	132,810
Total			4,139,040	432,810

- (b) Post-employment benefits
- © Other long term benefits
- (d) Termination benefits and
- (e) Share-based payment

01/07/2025 to 31/03/2026
Nil
Nil
Nil
Nil

41.00 Significant Deviation

During the period from July 1, 2025 to March 31, 2026, the Company's Net Profit after Tax and Earnings per Share (EPS) decreased compared to the same period of the previous year, primarily due to a decline in sales volume.

The Net Operating Cash Flow per Share (NOCFPS) also decreased during the period, mainly attributable to lower sales and reduced collections from receivables.

Furthermore, the Net Asset Value (NAV) per share declined as a result of the net loss incurred during the period.